These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 33469328)

  • 21. Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin.
    Shah VN; Franek E; Wernicke-Panten K; Pierre S; Mukherjee B; Sadeharju K
    Diabetes Ther; 2021 Feb; 12(2):557-568. PubMed ID: 33432547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(20):1-58. PubMed ID: 23074525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study.
    Odawara M; Kadowaki T; Naito Y
    J Diabetes Complications; 2015; 29(1):127-33. PubMed ID: 25449981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
    Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis.
    Yang LJ; Wu TW; Tang CH; Peng TR
    BMC Endocr Disord; 2022 Feb; 22(1):35. PubMed ID: 35123455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2).
    Miura H; Sakaguchi K; Okada Y; Otowa-Suematsu N; Yamada T; So A; Komada H; Hirota Y; Kishi M; Takeda A; Tominaga Y; Nakamura T; Kuroki Y; Matsuda T; Iida K; Kajikawa M; Ohara T; Yokota K; Hara K; Tateya S; Tamori Y; Ogawa W
    Diabetes Ther; 2018 Dec; 9(6):2399-2406. PubMed ID: 30341665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine.
    Fisher A; Kim JD; Dormuth C
    Clin Ther; 2022 Jul; 44(7):957-970.e12. PubMed ID: 35691731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn.
    Matli MC; Wilson AB; Rappsilber LM; Sheffield FP; Farlow ML; Johnson JL
    J Diabetes Sci Technol; 2023 Mar; 17(2):490-494. PubMed ID: 34971335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M).
    Aravind SR; Singh KP; Aquitania G; Mogylnytska L; Zalevskaya AG; Matyjaszek-Matuszek B; Wernicke-Panten K; Nguyên-Pascal ML; Pierre S; Rotthaeuser B; Kramer D; Mukherjee B
    Diabetes Ther; 2022 May; 13(5):1053-1071. PubMed ID: 35420397
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Rosdiana DS; Setiabudy R; Andalusia R; Gatot D; Louisa M; Bardosono S; Instiaty I
    Pharmgenomics Pers Med; 2021; 14():199-210. PubMed ID: 33568932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes.
    Heller S; Raposo JF; Tofé S; Hanif W; Schroner Z; Down S; Blevins T
    Clin Diabetes; 2023; 41(2):154-162. PubMed ID: 37092154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilar insulin concepts.
    Bloomgarden ZT
    J Diabetes; 2022 Apr; 14(4):231-235. PubMed ID: 35347893
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.
    Derwahl KM; Bailey TS; Wernicke-Panten K; Ping L; Pierre S
    Diabetes Technol Ther; 2018 Jan; 20(1):49-58. PubMed ID: 29232162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes.
    Tarigan TJE; Dwijayanti A; Setyowati S; Louisa M
    Diabetes Metab Syndr Obes; 2021; 14():107-116. PubMed ID: 33469328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.
    Christofides EA; Stankiewicz A; Denham D; Bellido D; Franek E; Nakhle S; Łukaszewicz M; Reed J; Cózar-León V; Kosch C; Karaś P; Fitz-Patrick D; Handelsman Y; Warren M; Hollander P; Huffman D; Raskin P; Oroszlán T; Lillestol M; Ovalle F
    Endocr Pract; 2024 Sep; 30(9):810-816. PubMed ID: 38876181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.